ASCO 2022 Small Bytes: Dr. Alexander I. Spira on KRYSTAL-1 for Patients with Advanced/Metastatic NSCLC

Published: June 6, 2022, 8:33 p.m.

At the ASCO 2022 Annual Meeting, Oncology Times reporter Peter Goodwin caught up with Alexander I. Spira, MD, PhD, FACP after his presentation on KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non\u2013small cell lung cancer (NSCLC) harboring a KRASG12C mutation (Abstract 9002).